2/13
04:15 pm
nktr
Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Low
Report
Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
2/11
10:23 pm
nktr
Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering
Medium
Report
Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering
2/11
11:51 am
nktr
Nektar Stock Surges On Rezpegaldesleukin Phase 2b Maintenance Data: What It Means [Seeking Alpha]
Low
Report
Nektar Stock Surges On Rezpegaldesleukin Phase 2b Maintenance Data: What It Means [Seeking Alpha]
2/10
04:30 pm
nktr
Nektar Therapeutics (NKTR) Discusses 36-Week Maintenance Results From Phase 2b REZOLVE-AD Study in Atopic Dermatitis Transcript [Seeking Alpha]
High
Report
Nektar Therapeutics (NKTR) Discusses 36-Week Maintenance Results From Phase 2b REZOLVE-AD Study in Atopic Dermatitis Transcript [Seeking Alpha]
2/10
04:05 pm
nktr
Nektar Therapeutics Announces Proposed Public Offering
High
Report
Nektar Therapeutics Announces Proposed Public Offering
2/10
01:32 pm
nktr
Nektar Therapeutics (NASDAQ:NKTR) had its price target raised by analysts at HC Wainwright from $135.00 to $165.00. They now have a "buy" rating on the stock.
Medium
Report
Nektar Therapeutics (NASDAQ:NKTR) had its price target raised by analysts at HC Wainwright from $135.00 to $165.00. They now have a "buy" rating on the stock.
2/10
01:00 pm
nktr
Nektar Therapeutics (NASDAQ:NKTR) had its price target raised by analysts at BTIG Research from $118.00 to $151.00. They now have a "buy" rating on the stock.
Medium
Report
Nektar Therapeutics (NASDAQ:NKTR) had its price target raised by analysts at BTIG Research from $118.00 to $151.00. They now have a "buy" rating on the stock.
2/10
12:00 pm
nktr
Nektar Therapeutics (NASDAQ:NKTR) was upgraded by analysts at William Blair from a "market perform" rating to an "outperform" rating.
Medium
Report
Nektar Therapeutics (NASDAQ:NKTR) was upgraded by analysts at William Blair from a "market perform" rating to an "outperform" rating.
2/10
07:00 am
nktr
New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing
High
Report
New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing
2/9
04:15 pm
nktr
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026
High
Report
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026
2/2
10:09 pm
nktr
Nektar Therapeutics (NKTR): A Bull Case Theory [Yahoo! Finance]
Medium
Report
Nektar Therapeutics (NKTR): A Bull Case Theory [Yahoo! Finance]
1/30
05:58 pm
nktr
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
1/30
04:10 pm
nktr
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/29
12:30 pm
nktr
Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $118.00 price target on the stock.
Low
Report
Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $118.00 price target on the stock.
1/27
01:42 pm
nktr
An immune drug developer raises $50M to finance its eczema drug testing [Yahoo! Finance]
Low
Report
An immune drug developer raises $50M to finance its eczema drug testing [Yahoo! Finance]
1/26
10:59 am
nktr
Nektar Therapeutics (NASDAQ:NKTR) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Low
Report
Nektar Therapeutics (NASDAQ:NKTR) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
1/22
10:00 am
nktr
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
1/20
04:20 pm
nktr
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
1/15
10:00 am
nktr
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
1/13
04:28 pm
nktr
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
1/8
10:00 am
nktr
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
1/7
08:35 am
nktr
How The Narrative Around Nektar Therapeutics (NKTR) Is Shifting With Rezpeg Data And Litigation Risks [Yahoo! Finance]
Low
Report
How The Narrative Around Nektar Therapeutics (NKTR) Is Shifting With Rezpeg Data And Litigation Risks [Yahoo! Finance]
1/6
11:50 am
nktr
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
1/1
10:00 am
nktr
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
12/30
12:40 pm
nktr
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR